
    
      This is a non randomized (the study medication is not assigned by chance), open-label (all
      participants and study staff know the identity of the treatment), multi-center, prospective
      (looking forward using observations collected following participant enrollment), and
      non-comparative study in which participants with erectile dysfunction will be observed to
      evaluate the safety and effectiveness of mirodenafil for 12 weeks. Safety evaluations will
      include assessment of adverse events, and record of concomitant medications. The study will
      be conducted in Korea.
    
  